Full Press Release Details
pozelimab c5 antibody bla for treatment of children and adults with ultra rare chaple disease accepted for fda priority review.
REGN
pozelimab c5 antibody bla for treatment of children and adults with ultra rare chaple disease accepted for fda priority review
Key Takeaway: pozelimab c5 antibody bla for treatment of children and adults with ultra rare chaple disease accepted for fda priority review